FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
“We credit FDA with taking decisive action to help advance Accelerated Approval discussions regarding OST-HER2 for pediatric cancer patients with osteosarcoma,” said Paul Romness, MPH, Chairman & CEO of OS Therapies. “With the biomarker analysis complete, and patent filings in process, we are poised to deliver data to the agency that we believe represents surrogate clinical efficacy sufficient to enable our ongoing BLA submission. Following key meetings with Key Opinion Leaders over the last few weeks, many of whom treated patients in our clinical trial, we believe we now have a clear path forward to establish confirmatory randomized Phase 3 trial that is required to have a commenced prior to being granted Accelerated Approval in the United States.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines